Research Output
CD3 limits the efficacy of TCR gene therapy in vivo
  The function of T-cell receptor (TCR) gene modified T cells is dependent on efficient surface expression of the introduced TCR / heterodimer. We tested whether endogenous CD3 chains are rate-limiting for TCR expression and antigen-specific T-cell function. We show that co-transfer of CD3 and TCR genes into primary murine T cells enhanced TCR expression and antigen-specific T-cell function in vitro. Peptide titration experiments showed that T cells expressing introduced CD3 and TCR genes recognized lower concentration of antigen than T cells expressing TCR only. In vivo imaging revealed that TCRCD3 gene modified T cells infiltrated tumors faster and in larger numbers, which resulted in more rapid tumor elimination compared with T cells modified by TCR only. After tumor clearance, TCRCD3 engineered T cells persisted in larger numbers than TCR only T cells and mounted a more effective memory response when rechallenged with antigen. The data demonstrate that provision of additional CD3 molecules is an effective strategy to enhance the avidity, anti-tumor activity and functional memory formation of TCR gene modified T cells in vivo.

  • Type:

    Article

  • Date:

    12 July 2011

  • Publication Status:

    Published

  • Publisher

    American Society of Hematology

  • DOI:

    10.1182/blood-2011-04-346338

  • ISSN:

    0006-4971

Citation

Ahmadi, M., King, J. W., Xue, S. A., Voisine, C., Holler, A., Wright, G. P., …Stauss, H. J. (2011). CD3 limits the efficacy of TCR gene therapy in vivo. Blood, 118(13), 3528-3537. https://doi.org/10.1182/blood-2011-04-346338

Authors

Keywords

Immunology; Cell Biology; Biochemistry; Hematology

Monthly Views:

Available Documents